Mediastinal Mass Assessment

Mediastinal mass assessment determines lymphatic involvement affecting staging and prognosis. Computed tomography establishes mass dimensions. Positron emission tomography detects metabolic activity. Biopsy provides definitive histological diagnosis. Treatment response assessment employs serial imaging.

Regulatory submissions incorporate mediastinal assessment. Clinical outcomes correlate with staging. Therapeutic response monitoring guides treatment adjustments. Post-approval surveillance tracks mass-related events. Emerging imaging improves diagnostic accuracy.